Monday, 7 May 2012
AUDIO: Novartis defends eye drug cost
The NHS could save £84m a year by using a cheaper drug to treat a leading cause of blindness, research suggests. NHS-funded research says both Lucentis and Avastin have a similar effect in preventing loss of sight when used for wet age-related macular degeneration. Lucentis costs about £700 an injection and Avastin £60 - but Avastin is not officially approved for eye conditions. Novartis, which markets Lucentis in the UK, is taking legal action against four NHS trusts for using the cheaper
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment